Cargando…

An 8-year longitudinal study of long-acting injectable (LAI) antipsychotics. Prescription trends and therapeutic drug monitoring to inform precision dosing

INTRODUCTION: Despite the widespread use of long-acting injectable (LAI) antipsychotics in schizophrenia and other disorders, there is a lack of longitudinal studies evaluating prescription trends and the usefulness of therapeutic drug monitoring (TDM) to inform dosing. Indeed, LAI prescription vari...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piacentino, D., Carpi, F., Giupponi, G., Conca, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565748/ http://dx.doi.org/10.1192/j.eurpsy.2022.482

Ejemplares similares

Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania
por: Miron, Ana A., et al.
Publicado: (2022)

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia
por: Potkin, Steven, et al.
Publicado: (2013)

The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia
por: STRUNOIU, LIVIA MIHAELA, et al.
Publicado: (2021)

Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
por: McKee, Kyle A., et al.
Publicado: (2021)

Comparison of hospitalizations in patients on first generation versus second generation long acting injectable (LAI) antipsychotics
por: Rasool, Seemab, et al.
Publicado: (2021)

The Use of Long-Acting Injectable Antipsychotics (LAI) in the Serious Mental Illness (SMI) Patients Enrolled in an Assertive Community Treatment (ACT) Program
por: Yee, Maria Ruiza, et al.
Publicado: (2021)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo, Ilaria, et al.
Publicado: (2018)

F228. EFFECTIVENESS OF PALIPERIDONE PALMITATE VS OTHER LONG-ACTING INJECTABLE (LAI) ANTIPSYCHOTICS – AN ELECTRONIC CASE REGISTER STUDY
por: Patel, Rashmi, et al.
Publicado: (2018)

Psychiatric Nurses’ Knowledge and Practice Barriers to Administering Long-Acting Injectable (LAI) Antipsychotics in Taiwan: A Mixed-Methods Study
por: Lin, Yao-Yu, et al.
Publicado: (2023)

The place of Long Acting Injectables (LAI) in the treatment of Schizophrenia: Current perspectives
Publicado: (2022)

Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic
por: Haider, Batool, et al.
Publicado: (2023)

Population pharmacokinetics and dosing of long-acting injectable antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Efficacy and safety of second-generation antipsychotic long-acting injections (SGA LAIs) in maintenance treatment of bipolar disorder: protocol for a systematic review and meta-analysis
por: Prajapati, Asta R, et al.
Publicado: (2016)

Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset Schizophrenia
por: Viala, Annie, et al.
Publicado: (2012)

Side-effect monitoring of continuing LAI antipsychotic medication in UK adult mental health services
por: Paton, Carol, et al.
Publicado: (2021)

A study on blood pressure changes following Olanzapine Long Acting Injection (LAI) in schizophrenia
por: Gakkhar, Shivam, et al.
Publicado: (2022)

Lais /
por: France, Marie de
Publicado: (1994)

Schizophrenia treatment with a combination of two LAI antipsychotics: A case report
por: Jarosz, Marcin, et al.
Publicado: (2022)

T213. TREND OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS USE IN ASIA: FINDINGS FROM REAP ANTIPSYCHOTIC STUDIES
por: Lin, Shih-Ku, et al.
Publicado: (2020)

Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study
por: Janzen, Donica, et al.
Publicado: (2022)

T231. PALIPERIDONE LONG-ACTING INJECTABLE (LAI) IS ASSOCIATED WITH A LOWER INTAKE OF BENZODIAZEPINES AND A LOWER NUMBER OF ADMISSIONS COMPARED WITH OTHER LAIS IN A COHORT OF PATIENTS WITH SCHIZOPHRENIA
por: Garcia-Carmona, Juan-Antonio
Publicado: (2018)

Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products
por: Gomeni, Roberto, et al.
Publicado: (2022)

Therapeutic drug monitoring of LAI antipsychotics as a predictor of clinical relapse: a one-year follow-up
por: D’Anna, G., et al.
Publicado: (2022)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
por: Milz, Ruth, et al.
Publicado: (2023)

PM499. Improvement of cognitive function before and after 2-year treatment with long-acting injection (LAI) of antipsychotics evaluated by NIRS using single word-induced hemoglobin variation as an index
por: Shoji, Yoshihisa, et al.
Publicado: (2016)

Monitoring of Inter-Dose Intervals for Long-Acting Injectable Antipsychotics: A Proposed Protocol for the MIDILIA Trial
por: O'Neill, James, et al.
Publicado: (2023)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
por: Lauriello, John, et al.
Publicado: (2021)

Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics
por: Kheloussi, Steven, et al.
Publicado: (2022)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

Long-acting injectable antipsychotics during pregnancy: An update
por: Paraschakis, A., et al.
Publicado: (2021)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Estimating Leaf Area Index (LAI) in Vineyards Using the PocketLAI Smart-App
por: Orlando, Francesca, et al.
Publicado: (2016)

1562. Renal Outcomes after Switch from Oral Antiretroviral therapy (ART) to Long-acting injectable Cabotegravir/Rilpivirine (LAI CAB)
por: Ayala, Alvaro, et al.
Publicado: (2023)

Aripiprazole lai two-injection start in a 16 year-old with Schizophrenia
por: Marpepa, B., et al.
Publicado: (2022)

Materia de distintos lais /
por: Cervantes, Francisco, 1938-

Cannot write session to /tmp/vufind_sessions/sess_jv6vp5os9q32d006neqa6jl0sr